BRCA2 and ovarian cancer: Because hRAD52 and BRCA2 play distinct roles in DSB repair, we examined the ability of the RAD52 S346X truncation variant (Fig. 1A) to act as a modifier of susceptibility to breast and ovarian cancers in BRCA1 and BRCA2 mutation carriers.